- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed and/or refractory mantle cell lymphoma
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1614KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 352KB)
Zanubrutinib – July 2021
Zanubrutinib (RR MCL): Capsule 80 mg; Brukinsa®
Last updated
30 May 2025